PG
JAZZ icon

Pendal Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Pendal Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,567
Closed -$1.79M – 529
2020
Q3 		$1.79M Sell
12,567
-32,833
-72% -$4.07M 0.02% 189
2020
Q2 		$5.01M Sell
45,400
-4,743
-9% -$524K 0.07% 105
2020
Q1 		$5M Buy
50,143
+15,515
+45% +$2.01M 0.09% 87
2019
Q4 		$5.17M Buy
34,628
+14,647
+73% +$1.99M 0.07% 129
2019
Q3 		$2.56M Buy
19,981
+6,359
+47% +$852K 0.03% 182
2019
Q2 		$1.94M Buy
13,622
+2,079
+18% +$279K 0.03% 219
2019
Q1 		$1.65M Hold
11,543
– – 0.02% 245
2018
Q4 		$1.43M Buy
11,543
+3,209
+39% +$476K 0.02% 236
2018
Q3 		$1.4M Buy
8,334
+1,157
+16% +$199K 0.02% 260
2018
Q2 		$1.24M Sell
7,177
-8
-0.1% -$1.31K 0.02% 282
2018
Q1 		$1.08M Buy
7,185
+97
+1% +$14.2K 0.01% 314
2017
Q4 		$954K Buy
7,088
+122
+2% +$16.9K 0.01% 308
2017
Q3 		$1.02M Buy
6,966
+2,777
+66% +$420K 0.01% 308
2017
Q2 		$651K Buy
+4,189
New +$641K 0.01% 337

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Pendal Group's JAZZ Position: Q4 2020 in Review

Pendal Group sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2020, closing a stake of 12,567 shares — an estimated $1.79M sold.

Pendal Group first reported a position in JAZZ in Q2 2017 and held it in 14 quarters. The position peaked at $5.17M in Q4 2019. 437 funds tracked by Wall St. Rank hold JAZZ as of Q4 2020.

  • Pendal Group reported no remaining Jazz Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Pendal Group sold 12,567 Jazz Pharmaceuticals shares in Q4 2020, an estimated $1.79M.
  • Pendal Group first reported a position in Jazz Pharmaceuticals in Q2 2017 and held it in 14 quarters.
  • Pendal Group's Jazz Pharmaceuticals position peaked at $5.17M in Q4 2019.
  • 437 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2020.

Based on Pendal Group's 13F filing for Q4 2020, filed 21 Jan 2021.